Euronext N : Biom’up lists on Euronext Paris to finance its development

€38.1 million raised; market capitalisation approximately €113.4 million

Paris - 13 October 2017 - Biom'Up, a specialist in hemostatic products used in surgery, listed today in Compartment C of Euronext Paris, joining the community of over 330 small and mid-sized tech companies - including more than 80 operating in life sciences - on Euronext's pan-European markets.

Thanks to a world-renowned medical team and their scientific expertise in the field of biopolymers, Biom'Up has developed HEMOBLAST™ Bellows, a world-class hemostatic product that aims to control bleeding during surgical operations (e.g., spine, heart, orthopedic or general surgeries). Bleeding leads to complications during surgery and lengthens the surgical procedure. Therefore hemostatic products are crucial in surgical operations that present a significant risk of bleeding. Today these products represent a global growth market estimated at 2 billion dollars. The US and European markets already established (e.g., spine and cardiovascular surgeries) represent an opportunity of 1.2 billion dollars.

HEMOBLAST™ Bellows obtained the CE Mark in December 2016, and the PMA (Pre-Market Approval) application was submitted to the FDA (Food & Drug Administration) in July 2017 with a view to obtaining marketing approval in the United States in mid-2018.

Biom'Up (ticker code BUP) was listed through the admission to trading on 13 October 2017 of 10,802,907 shares including 3,631,579 new shares issued as part of a Global Offering including the full exercise of the extension option and excluding the potential exercise of the over-allotment option.

The offering price was set at €10.5 per share. Market capitalisation was around €113.4 million on the day of listing, and the IPO raised a total of €38.1 million.

At the listing ceremony, Etienne Binant, Chief Executive Officer of Biom'Up, said: 'I am very pleased to announce today the success of our IPO on the regulated market of Euronext in Paris. I welcome the new French, European and American shareholders, and thank them for their trust. This operation was made possible by the empowerment and the financial investment of the management team (Bill Spotnitz, João-Paulo Alves and Jan Ohrstrom), as well as the support of the historical shareholders. We are now in the most favourable conditions to deploy our range of hemostatic products - especially HEMOBLAST™ Bellows - in Europe and North America. We will maintain our R&D investments and conduct new clinical studies to gain access to new surgical indications for the benefit of patients and clinicians.'